Overview
Therapeutic Advancements for the Treatment of High-Risk MDS: Future Opportunities to Improve Patient Survival and Quality of Life
Digital FAQ
Click the "Start Activity" button to indicate you have reviewed the CME/CE information for this activity.
Start ActivitySpecialties: Hematology, Medical Oncology, Pathology
• Apply updated classification guidelines in the evaluation of patients with MDS.
• Outline the role of immune surveillance and CD47 in the development of MDS.
• Discuss unmet patient needs in the treatment of HR-MDS.
• Describe the MOA of emerging therapies.
Courtney DiNardo, MD, MSCE
Associate Professor
Department of Leukemia
Division of Cancer Medicine
The University of Texas MD Anderson Cancer Center
Houston, TX
Professor of Medicine
Clinical Director of Leukemia Services
Associate Chief of Clinical Affairs
Robert H. Allen MD Chair in Hematology Research
Division of Hematology
University of Colorado School of Medicine
Aurora, CO
The University of Texas MD Anderson Cancer Center adheres to the ACCME's Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a CE activity, including faculty, planners, reviewers or others are required to disclose all financial relationships with ineligible companies (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of the activity.
Faculty & Planner Disclosure:
Faculty | Individual's role in activity | Commercial Interest |
Katlyn Cooper | Planning Committee Member | Nothing to disclose |
Courtney DiNardo, MD | Co-Director, Faculty | Honoraria: AbbVie, Daiichi Sankyo, Gilead Sciences, Inc. (Relationship has ended), Genentech, Astellas (Relationship has ended), Bristol-Myers Squibb, GlaxoSmithKline, Jazz Pharmaceuticals, Novartis (Relationship has ended), Servier Pharmaceuticals, Immunogen (Relationship has ended) Grant or research support: Oncternal, Pharmacyclics LLC, Velosbio |
Michelle Forcier, MS | Planning Committee Members | Nothing to disclose |
Danya T. Garner, PhD, RN, NPD-BC, OCN, CCRN-K | Planning Committee Member, Nurse Planner | Nothing to disclose |
Lisa Keckich, MS | Planning Committee Members | Nothing to disclose |
Ritesh Kothari, MS | Planning Committee Members | Nothing to disclose |
Natasha Mitchner, PhD | Planning Committee Members | Nothing to disclose |
Ann Perch, MBA | Planning Committee Members | Nothing to disclose |
Daniel Pollyea, MD | Co-Director, Faculty | Grant or research support: AbbVie, Bristol-Myers Squibb, Teva Pharmaceutical Industries, Karyopharm Therapeutics; Honoraria-AbbVie Inc. (Relationship has ended), Novartis (Relationship has ended), Takeda (Relationship has ended), Kiadis (Relationship has ended), Foghorn (Relationship has ended), Aprea (Relationship has ended), Genentech, Syros (Relationship has ended), Gilead Sciences, Inc. (Relationship has ended), Astellas (Relationship has ended), Karyopharm Therapeutics (Relationship has ended), Syndax (Relationship has ended), Jazz Pharmaceuticals (Relationship has ended), Bristol-Myers Squibb Company (Relationship has ended), BeiGene (Relationship has ended), Bergen Bio (Relationship has ended) |
Vanessa Senatore | Planning Committee Members | Nothing to disclose |
Jonathan Sokolowski, PhD | Planning Committee Members | Nothing to disclose |
In support of improving patient care, The University of Texas MD Anderson Cancer Center is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.